IL-6联合NLR对三阴性乳腺癌术后患者预后的预测价值(1)
[摘要] 目的 探究白细胞介素-6(IL-6)联合中性粒细胞/淋巴细胞比值(NLR)对三阴性乳腺癌术后患者预后的预测价值。 方法 选择2015年1月～2017年12月辽宁省辽阳市中心医院行乳腺癌根治术的540例三阴性乳腺癌患者为研究对象，采用酶联免疫吸附法检测患者血清IL-6水平，采用血细胞分析仪检测中性粒细胞数及淋巴细胞数，计算NLR值。应用logistic回归分析三阴性乳腺癌预后不良的危险因素，采用受试者工作特征曲线(ROC)评估血清IL-6和NLR对患者预后的预测价值。出院后对患者预后情况进行随访。 结果 截至2019年9月30日，发生不良预后患者141例，发生率为26.11%。三阴性乳腺癌预后不良与肿瘤TNM分期、NLR和IL-6水平相關(P < 0.05)，logistic回归分析显示NLR(OR = 3.652，95%CI：1.804～7.918，P = 0.000)和IL-6水平(OR = 2.361，95%CI：2.169～2.770，P = 0.006)是三阴性乳腺癌预后不良的危险因素(P < 0.05)。ROC曲线显示，IL-6水平的截断值为128.06 ng/mL，敏感性为71.67%、特异性为70.83%，NLR的截断值为2.61，敏感性为75.31%、特异性为79.65%。 结论 NLR和血清IL-6水平的上升是三阴性乳腺癌预后不良的危险因素，联合检测NLR和血清IL-6可以提高其敏感性和特异度，并可预测患者不良预后。
[关键词] 白细胞介素-6;中性粒细胞/淋巴细胞比值;三阴性乳腺癌;预后
[中图分类号] R737.9 [文献标识码] A [文章编号] 1673-7210(2020)03(b)-0113-04
[Abstract] Objective To investigate the predictive value of interleukin-6(IL-6) combined with neutrophil/lymphocyte ratio (NLR) on the prognosis of patients with triple negative breast cancer after surgery. Methods A total of 540 patients with triple negative breast cancer who underwent radical mastectomy in Liaoyang City Central Hospital of Liaoning Province from January 2015 to December 2017 were selected as subjects. Serum IL-6 level of the patients was detected by enzyme-linked immunosorbent assay， and the number of neutrophils and lymphocytes were detected by hematology analyzer， and the NLR value was calculated. Logistic regression was used to analyze the risk factors of poor prognosis of triple negative breast cancer. Receiver operating curve (ROC) was used to evaluate the predictive value of serum IL-6 and NLR to the prognosis of patients. The prognosis of the patients was followed up after discharge. Results By the end of follow-up， 141 patients had poor prognosis， the incidence was 26.11%. The poor prognosis of triple negative breast cancer was correlated with TNM stage， NLR and IL-6 levels (P < 0.05). Logistic regression analysis showed that NLR (OR = 3.652， 95%CI：1.804-7.918， P = 0.000) and IL-6 levels (OR = 2.361， 95%CI：2.169-2.770， P = 0.006) were risk factors for poor prognosis of triple negative breast cancer (P < 0.05). ROC curve showed that the cutoff value of IL-6 was 128.06 ng/mL， the sensitivity was 71.67% and the specificity was 70.83%， the cutoff value of NLR was 2.61， the sensitivity was 75.31% and the specificity was 79.65%. Conclusion Increased levels of NLR and serum IL-6 are risk factors for poor prognosis in triple negative breast cancer. Combined testing for NLR and serum IL-6 can improve sensitivity and specificity and predict poor prognosis in patients., 百拇医药(刘军玲 周革 郭宏斌)
[关键词] 白细胞介素-6;中性粒细胞/淋巴细胞比值;三阴性乳腺癌;预后
[中图分类号] R737.9 [文献标识码] A [文章编号] 1673-7210(2020)03(b)-0113-04
[Abstract] Objective To investigate the predictive value of interleukin-6(IL-6) combined with neutrophil/lymphocyte ratio (NLR) on the prognosis of patients with triple negative breast cancer after surgery. Methods A total of 540 patients with triple negative breast cancer who underwent radical mastectomy in Liaoyang City Central Hospital of Liaoning Province from January 2015 to December 2017 were selected as subjects. Serum IL-6 level of the patients was detected by enzyme-linked immunosorbent assay， and the number of neutrophils and lymphocytes were detected by hematology analyzer， and the NLR value was calculated. Logistic regression was used to analyze the risk factors of poor prognosis of triple negative breast cancer. Receiver operating curve (ROC) was used to evaluate the predictive value of serum IL-6 and NLR to the prognosis of patients. The prognosis of the patients was followed up after discharge. Results By the end of follow-up， 141 patients had poor prognosis， the incidence was 26.11%. The poor prognosis of triple negative breast cancer was correlated with TNM stage， NLR and IL-6 levels (P < 0.05). Logistic regression analysis showed that NLR (OR = 3.652， 95%CI：1.804-7.918， P = 0.000) and IL-6 levels (OR = 2.361， 95%CI：2.169-2.770， P = 0.006) were risk factors for poor prognosis of triple negative breast cancer (P < 0.05). ROC curve showed that the cutoff value of IL-6 was 128.06 ng/mL， the sensitivity was 71.67% and the specificity was 70.83%， the cutoff value of NLR was 2.61， the sensitivity was 75.31% and the specificity was 79.65%. Conclusion Increased levels of NLR and serum IL-6 are risk factors for poor prognosis in triple negative breast cancer. Combined testing for NLR and serum IL-6 can improve sensitivity and specificity and predict poor prognosis in patients., 百拇医药(刘军玲 周革 郭宏斌)
参见：首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌